Sitagliptin/Metformin Medical Valley Filmuhúðuð tafla 50mg/850 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sitagliptin/metformin medical valley filmuhúðuð tafla 50mg/850 mg

medical valley invest ab - sitagliptinum hýdróklóríð; metforminum hýdróklóríð - filmuhúðuð tafla - 50mg/850 mg

Terbinafin Medical Valley Tafla 250 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

terbinafin medical valley tafla 250 mg

medical valley invest ab - terbinafinum hýdróklóríð - tafla - 250 mg

Loperamide Medical Valley Tafla 2 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

loperamide medical valley tafla 2 mg

medical valley invest ab - loperamidum hýdróklóríð - tafla - 2 mg

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Evrópusambandið - íslenska - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klópídógrel hýdróklóríð - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - blóðþurrðandi lyf - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Centyl með kaliumklorid Filmuhúðuð tafla 2,5 mg+573 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

centyl með kaliumklorid filmuhúðuð tafla 2,5 mg+573 mg

karo pharma ab* - bendroflumethiazidum inn; kalii chloridum - filmuhúðuð tafla - 2,5 mg+573 mg

Centyl mite með kaliumklorid Filmuhúðuð tafla 1,25 mg/573 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

centyl mite með kaliumklorid filmuhúðuð tafla 1,25 mg/573 mg

karo pharma ab* - kalii chloridum; bendroflumethiazidum inn - filmuhúðuð tafla - 1,25 mg/573 mg